Lixte Biotechnology Warrants
LIXTW
LIXTW was delisted on the 26th of November, 2025.
2 hedge funds and large institutions have $5.6K invested in Lixte Biotechnology Warrants in 2022 Q4 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 1 closing their positions.
12% more capital invested
Capital invested by funds: $5K → $5.6K (+$602)
0.07% less ownership
Funds ownership: 0.66% → 0.59% (-0.07%)
33% less funds holding
Funds holding: 3 → 2 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$323 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CS
1
Clear Street
New York
| $5K | – | – | – |
|
|
2
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $602 | -$323 | -4,253 | -25% |
|
LIXTW Hedge Fund Activity: Q4 2022 in Review
2 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Lixte Biotechnology Warrants (LIXTW) for Q4 2022, worth a combined $5.6K — up 12% from $5K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of LIXTW and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 0 added.
The largest seller was Susquehanna International Group, cutting an estimated $323.
- 2 institutional investors held Lixte Biotechnology Warrants (LIXTW) as of Q4 2022, down from 3 in Q3 2022.
- Funds reported $5.6K of Lixte Biotechnology Warrants stock for Q4 2022, up 12% quarter-over-quarter.
- 0 funds opened new Lixte Biotechnology Warrants positions in Q4 2022 and 1 closed out, a net change of -1 holder.
- The largest Lixte Biotechnology Warrants seller in Q4 2022 was Susquehanna International Group, an estimated $323 sold.
Based on aggregated 13F filings for Q4 2022.